Studio post-marketing sul mastice MagnetOs rispetto all'innesto autologo in pazienti sottoposti a fusione lombare posterolaterale (PROOF)
Uno studio prospettico, randomizzato, a centro singolo per valutare la sicurezza e le prestazioni del mastice MagnetOs rispetto all'autoinnesto in pazienti sottoposti a fusione posterolaterale lombare/toracolombare strumentata a due livelli (PLF)
This is a phase IV post-marketing study for MagnetOs Easypack Putty. MagnetOs Easypack Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease or spinal trauma undergoing spinal fusion surgery.
In this study, MagnetOs Easypack Putty will be used according to the latest U.S. Instructions For Use, standalone in the posterolateral spine.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
In this study, following a screening period of a maximum of 30 days, 60 patients will undergo up to two-level instrumented posterolateral fusion (PLF) procedure. Prior to surgery, each patient will be randomized to receive MagnetOs Easypack Putty standalone on the assigned side of the spine and Demineralized Bone Matrix or Fibers mixed with local autograft bone on the other at the diseased levels. They will be followed up at discharge, Week 2, Month 3, Month 6, and Month 12. An interim analysis will be performed once 30 patients have completed their Month 6 visit and have measurements for the endpoints available to measure effectiveness. The primary endpoint will be analyzed at Month 12.
In this study, MagnetOs Easypack Putty will be applied according to the latest Instructions for Use approved in the United States. Specifically, MagnetOs Easypack Putty will be used standalone in patients up to two-level degenerative disc disease with segmental mechanical spinal instability requiring treatment with an instrumented posterolateral spine fusion procedure. The fusion procedure (PLF) will be left to the surgeon's discretion.
Radiographs will be obtained at Screening, Discharge, Month 3, Month 6 and Month 12. CT scans will only be obtained at Month 6 and Month 12.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
California
-
Irvine, California, Stati Uniti, 92697
- The Regents of the University of California- Irvine Campus
-
-
Michigan
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Corewell Health
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63130
- The Washington University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Rothman Orthopaedic Institute
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37209
- Tennessee Orthopaedic Alliance
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98104
- University of Washington
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patient is able to read/be read, understand, and provide written informed consent and has signed the Institutional Review Board (IRB) approved informed consent.
- Male or female patient ≥ 18 years old.
- Patients with segmental mechanical spinal instability requiring arthrodesis surgery.
Instability can be either caused by degenerative disc disease or by traumatic injury to the spinal column. Patient requiring a maximum of two-level instrumented posterolateral lumbar/thoraco-lumbar fusion (T11 - S1) will be enrolled. Mechanical instability is defined by the presence of one or more of the following:
-
instability (angulation ≥ 5 degrees or translation ≥ 3 mm on flexion/extension radiographs),
-
decreased disc height by > 2 mm, but dependent upon the spinal level
-
Grade II or more listhesis
-
TLICS equal or greater than 5
-
Unstable burst fracture
- Failed conservative treatment (physical therapy, bed rest, medications, spinal injections, manipulations, or transcutaneous electrical nerve stimulation) for a minimum period of 3 months prior to study enrollment (if the patient undergoes elective surgery). Patients who have spinal instability (as defined above in inclusion criteria number three), caused by acute trauma requiring urgent surgical treatment are excluded from this criterion.
Exclusion Criteria:
- Requires > two-level fusion or expected to need secondary intervention within one year following surgery.
- Had prior PLF fusion or attempted PLF fusion at the involved levels.
- Had previous decompression at the involved levels.
- Women who are or intend to become pregnant within the next 12 months.
- To treat conditions in which general bone grafting is not advisable.
- In conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g. defect site stabilization is not possible).
- In case of significant vascular impairment proximal to the graft site.
- In case of severe metabolic or systemic bone disorders (e.g., osteogenesis imperfecta, history of or active Pott's disease, stage >4 renal disease or Paget's Disease) that affect bone or wound healing.
- In case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis).
- When intraoperative soft tissue coverage is not planned or possible.
- Receiving treatment with medication interfering with calcium metabolism.
- Has degenerative disc disease (DDD) related to a benign or malignant tumor.
- Has history or presence of active malignancy.
- Has known substance abuse, psychiatric disorder, or a condition which, in the opinion of the investigator, may influence the healing or ability to comply with protocol requirements.
- Is involved in active litigation relating to his/her spinal condition.
- Has participated in an investigational study within 30 days prior to surgery for study devices.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: MagnetOs Easypack Putty
Interventions
|
MagnetOs Easypack Putty used standalone in instrumented posterolateral fusion, 5cc-15c per spine level at the randomized assigned side. |
|
Comparatore attivo: Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed with local autograft bone
Interventions
|
Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed in a 1:1 vol% with local autologous bone graft used in instrumented posterolateral fusion, 5cc-15cc per level mixed with bone marrow aspirate/blood per spine level at the contralateral side. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Radiographic Fusion by CT Scan
Lasso di tempo: Month 12
|
The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 12. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes. |
Month 12
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Radiographic Fusion by Plain Radiographs
Lasso di tempo: Month 6, Month 12
|
The rate of posterolateral lumbar/thoracolumbar fusion assessed by plain radiographs. |
Month 6, Month 12
|
|
Radiographic Fusion by CT Scan
Lasso di tempo: Month 6
|
The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 6. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes. |
Month 6
|
|
Functional Outcome by Oswestry Disability Index Questionnaire
Lasso di tempo: Screening, Week 2, Month 3, 6, and 12
|
Functional outcome by the Oswestry Disability Index questionnaire. Patient-completed questionnaire which gives a subjective percentage score of level of function (disability) in activities of daily living in those rehabilitating from low back pain. The lower the percentage the higher the patient's functionality. 0-20% minimal disability, 80-100% significant disability or bedridden. |
Screening, Week 2, Month 3, 6, and 12
|
|
Back and Leg Pain by Visual Analog Pain Scale Questionnaire
Lasso di tempo: Screening, Week 2, Month 3, 6, and 12
|
Change in back and leg pain using Visual Analog Pain Scale (0-100). Patient-completed questionnaire scoring pain by using 100 mm line. Zero being no pain, 100 is worst pain imaginable. |
Screening, Week 2, Month 3, 6, and 12
|
|
Neurologic Status by Physical Exam
Lasso di tempo: Screening, Week 2, Month 3, 6, and 12
|
Change in neurologic status by examination to document stable, improved, or deficits in condition. Stable or improved findings for lower extremities, specifically reflexes, muscle strength, sensory, and straight leg raise. |
Screening, Week 2, Month 3, 6, and 12
|
|
Success Rate
Lasso di tempo: Week 2, Month 3, 6, and 12
|
Number of patients with secondary surgical interventions (SSI's) such as revisions, re-operations, removals, supplemental fixations, or any other procedure that adjusts or removes part of the original implant configuration with or without replacement of the components within 12 months of surgery. |
Week 2, Month 3, 6, and 12
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Safety Endpoint - number of patients with Adverse Events
Lasso di tempo: 12 Months
|
The number of patients with Adverse Events from Screening up to Month 12 after surgery. |
12 Months
|
|
Safety Endpoint - number of patients with Serious Adverse Events
Lasso di tempo: 12 Months
|
The number of patients with Serious Adverse Events from Screening up to Month 12 after surgery |
12 Months
|
|
Safety Endpoint - number of patients with Adverse Device Effects
Lasso di tempo: 12 Months
|
The number of patients with Adverse Device Effects from Screening up to Month 12 after surgery. |
12 Months
|
|
Safety Endpoint - number of patients with Device Related Complications
Lasso di tempo: 12 Months
|
The number of patients with any complications considered to device related with 12 months after surgery. |
12 Months
|
|
Health Economic - Duration of Surgery
Lasso di tempo: 12 Months
|
Duration of surgery in minutes. |
12 Months
|
|
Health Economic - Duration of Hospitalization
Lasso di tempo: 12 Months
|
Duration of hospital stay in days. |
12 Months
|
|
Health Economic - Return to Work
Lasso di tempo: 12 Months
|
Time to return to work in days. |
12 Months
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Direttore dello studio: Cesar Silva, MD, Kuros BioSciences B.V.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- MAG-920-023
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .